Thomas Powles
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Thomas Powles
Jun 28, 2024, 14:34 |
Blog
María Natalia Gandur Quiroga: Imfinzi Shows Significant Survival Benefits in NIAGARA Phase III Trial
María Natalia Gandur Quiroga shared on LinkedIn: . "Imfinzi Shows Significant Survival Benefits in NIAGARA…
Jun 26, 2024, 08:30 |
Insight
IMFINZI (durvalumab) showed improved EFS and OS for MIBC in NIAGARA Phase III trial
First immunotherapy regimen before and after surgery to extend survival in bladder cancer Positive high-level results…
Apr 20, 2024, 06:03 |
Insight
Toni Choueiri: The long-awaited OS results from KEYNOTE-564 are out at the New England Journal of Medicine!
Toni Choueiri shared on X/Twitter: "The long-awaited OS results from KEYNOTE-564 are out at the New…
Feb 1, 2024, 15:42 |
Opinion
Thomas Powles: Enfortumab Vedotin and Pembrolizumab shows broad spectrum of activity for Regional Recurrence, Progression-free survival and Overall Survival in all subgroups
Jan 31, 2024, 15:42 |
Blog
Thomas Powles: We need better biomarkers in Urothelial Carcinoma
Thomas Powles, Director of Barts Cancer Centre, shared a post on X/Twitter: "Microsatellite instability (MSIH)…
All:
5
Posts:
1 - 100
Monica Bertagnolli: Molecular Portrait of Key Driver of pancreatic cancer
We need to hurry up, because cancer and patients cannot wait!
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
Facebook
RSS Feed
Twitter
Linkedin
Youtube